$HRMY
Harmony Biosciences Holdings Inc

2023 Q3 Form 10-Q Financial Statement

#000155837023012637 Filed on August 01, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $160.3M $134.2M
YoY Change 36.74% 25.4%
Cost Of Revenue $32.30M $25.01M
YoY Change 40.67% 32.17%
Gross Profit $128.0M $109.2M
YoY Change 35.78% 23.95%
Gross Profit Margin 79.85% 81.37%
Selling, General & Admin $45.96M $47.34M
YoY Change 9.97% 11.85%
% of Gross Profit 35.92% 43.35%
Research & Development $17.50M $14.97M
YoY Change -56.84% 18.16%
% of Gross Profit 13.67% 13.71%
Depreciation & Amortization $6.200M $6.064M
YoY Change 2.26% 0.15%
% of Gross Profit 4.84% 5.55%
Operating Expenses $63.46M $62.31M
YoY Change -22.93% 13.3%
Operating Profit $64.51M $46.90M
YoY Change 442.05% 41.63%
Interest Expense -$2.906M -$2.776M
YoY Change -27.17% -29.31%
% of Operating Profit -4.5% -5.92%
Other Income/Expense, Net -$5.000K -$31.00K
YoY Change -108.93% -173.81%
Pretax Income $51.83M $44.10M
YoY Change 550.58% 50.85%
Income Tax $13.37M $9.795M
% Of Pretax Income 25.8% 22.21%
Net Earnings $38.46M $34.30M
YoY Change -56.27% 45.77%
Net Earnings / Revenue 24.0% 25.56%
Basic Earnings Per Share $0.64 $0.57
Diluted Earnings Per Share $0.63 $0.56
COMMON SHARES
Basic Shares Outstanding 60.00M 59.95M
Diluted Shares Outstanding 60.68M 60.74M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $370.7M $371.0M
YoY Change 20.45% 45.96%
Cash & Equivalents $324.6M $317.4M
Short-Term Investments $46.10M $53.57M
Other Short-Term Assets $5.704M $15.99M
YoY Change 38.85% 335.27%
Inventory $5.087M $4.854M
Prepaid Expenses $14.27M $9.442M
Receivables $67.26M $63.81M
Other Receivables $0.00 $0.00
Total Short-Term Assets $463.0M $455.6M
YoY Change 21.18% 41.2%
LONG-TERM ASSETS
Property, Plant & Equipment $428.0K $2.629M
YoY Change -37.06% 278.27%
Goodwill
YoY Change
Intangibles $143.1M $149.0M
YoY Change -14.29% -13.79%
Long-Term Investments $67.70M $58.65M
YoY Change 717.63% 1135.54%
Other Assets $2.836M $94.23M
YoY Change -7.89% 2786.98%
Total Long-Term Assets $314.8M $304.5M
YoY Change 20.42% 67.03%
TOTAL ASSETS
Total Short-Term Assets $463.0M $455.6M
Total Long-Term Assets $314.8M $304.5M
Total Assets $777.8M $760.2M
YoY Change 20.87% 50.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.539M $6.563M
YoY Change -34.93% -1.47%
Accrued Expenses $72.76M $73.32M
YoY Change -15.0% 60.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $15.00M $11.00M
YoY Change 650.0% 450.0%
Total Short-Term Liabilities $112.4M $93.05M
YoY Change 4.7% 41.48%
LONG-TERM LIABILITIES
Long-Term Debt $182.1M $180.5M
YoY Change -4.0% -4.91%
Other Long-Term Liabilities $1.895M $1.479M
YoY Change -24.14% -49.52%
Total Long-Term Liabilities $184.0M $182.0M
YoY Change -4.26% -5.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $112.4M $93.05M
Total Long-Term Liabilities $184.0M $182.0M
Total Liabilities $296.4M $275.0M
YoY Change -1.05% 6.39%
SHAREHOLDERS EQUITY
Retained Earnings -$169.9M -$208.3M
YoY Change -47.02% -49.01%
Common Stock $651.7M $694.0M
YoY Change -1.95% 5.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $481.3M $485.2M
YoY Change
Total Liabilities & Shareholders Equity $777.8M $760.2M
YoY Change 20.87% 50.52%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $38.46M $34.30M
YoY Change -56.27% 45.77%
Depreciation, Depletion And Amortization $6.200M $6.064M
YoY Change 2.26% 0.15%
Cash From Operating Activities $63.10M $37.06M
YoY Change 14.3% 9.88%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $205.0K
YoY Change -100.0% -600.0%
Acquisitions
YoY Change
Other Investing Activities -$800.0K -$7.566M
YoY Change -97.53% -66.23%
Cash From Investing Activities -$800.0K -$7.771M
YoY Change -97.53% -65.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -55.10M -339.0K
YoY Change -2787.8% -145.2%
NET CHANGE
Cash From Operating Activities 63.10M 37.06M
Cash From Investing Activities -800.0K -7.771M
Cash From Financing Activities -55.10M -339.0K
Net Change In Cash 7.200M 28.95M
YoY Change -70.98% 140.59%
FREE CASH FLOW
Cash From Operating Activities $63.10M $37.06M
Capital Expenditures $0.00 $205.0K
Free Cash Flow $63.10M $36.86M
YoY Change 14.12% 9.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2023Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2022Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2023Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
dei Entity Central Index Key
EntityCentralIndexKey
0001802665
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q2 us-gaap Other Receivable After Allowance For Credit Loss Related Party Type Extensible Enumeration
OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4 us-gaap Other Receivable After Allowance For Credit Loss Related Party Type Extensible Enumeration
OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q2 us-gaap Other Liability Related Party Type Extensible Enumeration
OtherLiabilityRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4 us-gaap Other Liability Related Party Type Extensible Enumeration
OtherLiabilityRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2023Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39450
dei Entity Registrant Name
EntityRegistrantName
HARMONY BIOSCIENCES HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2279923
dei Entity Address Address Line1
EntityAddressAddressLine1
630 W.
dei Entity Address Address Line2
EntityAddressAddressLine2
Germantown Pike
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 215
dei Entity Address City Or Town
EntityAddressCityOrTown
Plymouth Meeting
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19462
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
539-9800
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 value per share
dei Trading Symbol
TradingSymbol
HRMY
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60000145
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
317415000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
243784000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
53568000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
79331000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
63812000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
54740000
CY2023Q2 us-gaap Inventory Net
InventoryNet
4854000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4297000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9442000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9347000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
6550000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
8786000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
455641000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
400285000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
572000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
573000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
250000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2023Q2 us-gaap Long Term Investments
LongTermInvestments
58651000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
22568000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
149031000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
160953000
CY2023Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
93578000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
85943000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2460000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2798000
CY2023Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
304542000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
273585000
CY2023Q2 us-gaap Assets
Assets
760183000
CY2022Q4 us-gaap Assets
Assets
673870000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6563000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3786000
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
7972000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
11532000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
63563000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
59942000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
11000000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3947000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1624000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
93045000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
78884000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
180487000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189647000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1479000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2501000
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
181966000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
192148000
CY2023Q2 us-gaap Liabilities
Liabilities
275011000
CY2022Q4 us-gaap Liabilities
Liabilities
271032000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59999658
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59999658
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59615731
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59615731
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
694038000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
675118000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-522000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-151000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-208345000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-272130000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
485172000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
402838000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
760183000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
673870000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
134216000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107028000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
253342000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
192341000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
25008000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18921000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
45788000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33637000
CY2023Q2 us-gaap Gross Profit
GrossProfit
109208000
CY2022Q2 us-gaap Gross Profit
GrossProfit
88107000
us-gaap Gross Profit
GrossProfit
207554000
us-gaap Gross Profit
GrossProfit
158704000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14969000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12668000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28258000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20246000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
24528000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20160000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
47100000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
37743000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22809000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22163000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44871000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40043000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
62306000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
54991000
us-gaap Operating Expenses
OperatingExpenses
120229000
us-gaap Operating Expenses
OperatingExpenses
98032000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
46902000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
33116000
us-gaap Operating Income Loss
OperatingIncomeLoss
87325000
us-gaap Operating Income Loss
OperatingIncomeLoss
60672000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-31000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
42000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
40000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2776000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-3927000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-5421000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8096000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
44095000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
29231000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
81875000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
52616000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9795000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5700000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18090000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7600000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
34300000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
23531000
us-gaap Net Income Loss
NetIncomeLoss
63785000
us-gaap Net Income Loss
NetIncomeLoss
45016000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-491000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-29000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-371000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-29000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
33809000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
23502000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
63414000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
44987000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.57
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.76
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.56
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.74
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59974123
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59063358
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59853808
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58986370
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60743953
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60922672
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60997410
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60759026
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
402838000
us-gaap Net Income Loss
NetIncomeLoss
63785000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-371000
hrmy Stock Issued During Period Value Stock Options And Restricted Stock Units Exercised
StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercised
4069000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14851000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
485172000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
443041000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
34300000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-491000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
674000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7648000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
485172000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186507000
us-gaap Net Income Loss
NetIncomeLoss
45016000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-29000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3133000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11906000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
246533000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
214503000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
23531000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-29000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1250000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7278000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
246533000
us-gaap Profit Loss
ProfitLoss
63785000
us-gaap Profit Loss
ProfitLoss
45016000
us-gaap Depreciation
Depreciation
206000
us-gaap Depreciation
Depreciation
211000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11922000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11043000
us-gaap Share Based Compensation
ShareBasedCompensation
14851000
us-gaap Share Based Compensation
ShareBasedCompensation
11906000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
-497000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
361000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
840000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
823000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-7635000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1312000
us-gaap Other Noncash Expense
OtherNoncashExpense
799000
us-gaap Other Noncash Expense
OtherNoncashExpense
770000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9072000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
14979000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
557000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-224000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2227000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3707000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2777000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
5660000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1289000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5407000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-152000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
79622000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
62583000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
72847000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
22406000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
63491000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
205000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
86000
hrmy Cash Paid For Milestones
CashPaidForMilestones
40000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9561000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-62492000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1000000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
514000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4584000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3133000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3070000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2133000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
73131000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2224000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
244534000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235059000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
317665000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
237283000
us-gaap Interest Paid Net
InterestPaidNet
10691000
us-gaap Interest Paid Net
InterestPaidNet
7524000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
19890000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
290000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-208345000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-272130000
CY2023Q2 us-gaap Investments And Cash
InvestmentsAndCash
429884000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes. </p>
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
317415000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
243784000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
250000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
317665000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
244534000
CY2023Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
347684000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
286876000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2731000
us-gaap Investment Income Interest
InvestmentIncomeInterest
5153000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
250000
us-gaap Investment Income Interest
InvestmentIncomeInterest
317000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Concentrations of Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s cash and money market funds are held in two financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company believes that it is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary. As of June 30, 2023, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 38% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 36% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 26% of gross accounts receivable. As of December 31, 2022, three customers accounted for 100% of gross accounts receivable; CVS Caremark, which accounted for 41% of gross accounts receivable, Accredo, which accounted for 35% of gross accounts receivable; and Pantherx, which accounted for 24% of gross accounts receivable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the six months ended June 30, 2023, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 35% of gross product revenues; Pantherx accounted for 33% of gross product revenues; and Accredo accounted for 32% of gross product revenues. For the six months ended June 30, 2022, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 39% of gross product revenues; Pantherx accounted for 32% of gross product revenues; and Accredo accounted for 29% of gross product revenues.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company depends on a single source supplier for each of its product and active pharmaceutical ingredient.</p>
hrmy Concentrations Of Risk Number Of Financial Institutions
ConcentrationsOfRiskNumberOfFinancialInstitutions
2
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
982000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
838000
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1679000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1513000
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2481000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2565000
CY2023Q2 us-gaap Inventory Gross
InventoryGross
5142000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
4916000
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
288000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
619000
CY2023Q2 us-gaap Inventory Net
InventoryNet
4854000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4297000
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5961000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5961000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11922000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11043000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
11923000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
23845000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
23845000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
23845000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
23845000
CY2023Q2 hrmy Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
41728000
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
149031000
CY2022Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
411000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
840000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
823000
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
6218000
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
4184000
CY2023Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
215000000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
215000000
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
65969000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
54047000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
149031000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
160953000
CY2023Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
22542000
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
25367000
CY2023Q2 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
30441000
CY2022Q4 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
27860000
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
4199000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3286000
CY2023Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2499000
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1135000
CY2023Q2 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1969000
CY2022Q4 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
358000
CY2023Q2 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
750000
CY2022Q4 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1163000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1163000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
773000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
63563000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
59942000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
196500000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
197500000
CY2023Q2 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
5013000
CY2022Q4 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
5853000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
191487000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
191647000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
11000000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
180487000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189647000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1000000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
20000000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
20000000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
155500000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
196500000
CY2023Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
5794000
CY2022Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
3773000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
11109000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
7597000
CY2023Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
424000
us-gaap Interest Expense Debt
InterestExpenseDebt
11949000
us-gaap Interest Expense Debt
InterestExpenseDebt
8420000
CY2018Q2 hrmy Operating Lease Office Space
OperatingLeaseOfficeSpace
15000
CY2018Q2 hrmy Operating Lease Additional Office Space Leased One
OperatingLeaseAdditionalOfficeSpaceLeasedOne
13000
CY2018Q2 hrmy Operating Lease Additional Office Space Leased Two
OperatingLeaseAdditionalOfficeSpaceLeasedTwo
7000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
444000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
392000
us-gaap Operating Lease Cost
OperatingLeaseCost
822000
us-gaap Operating Lease Cost
OperatingLeaseCost
777000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.047
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2057000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2312000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1786000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1614000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
452000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
975000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2238000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2589000
us-gaap Operating Lease Payments
OperatingLeasePayments
922000
us-gaap Operating Lease Payments
OperatingLeasePayments
872000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
615000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
465000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
992000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1135000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
176000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
20000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2323000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
85000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2238000
CY2022Q2 hrmy Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6460947
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
30.90
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M9D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
305828
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
37.27
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
355298
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
11.74
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
194620
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
24.57
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6216857
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.50
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M9D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7632
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8021
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7257
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7708
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0342
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0385
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0199
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0405
hrmy Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount
0.0000
CY2022 hrmy Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount
0.0000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7793000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7371000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14354000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12267000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
74153000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
14043
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
14043
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
14889
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
14889
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
34300000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
23531000
us-gaap Net Income Loss
NetIncomeLoss
63785000
us-gaap Net Income Loss
NetIncomeLoss
45016000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.57
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.76
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.56
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.74
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59974123
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59063358
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59853808
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58986370
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60743953
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60922672
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60997410
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60759026
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.005
CY2022Q2 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.005
us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.015
us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.020
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.040
CY2022Q2 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.072
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.051
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.072
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.029
us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.029
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.006
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004
CY2022Q2 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.082
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.118
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.222
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.195
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.221
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.144
CY2023Q2 us-gaap Other Liabilities
OtherLiabilities
0
CY2022Q4 us-gaap Other Liabilities
OtherLiabilities
0
CY2023Q2 us-gaap Other Receivables
OtherReceivables
0
CY2022Q4 us-gaap Other Receivables
OtherReceivables
0
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-23-012637-index-headers.html Edgar Link pending
0001558370-23-012637-index.html Edgar Link pending
0001558370-23-012637.txt Edgar Link pending
0001558370-23-012637-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hrmy-20230630.xsd Edgar Link pending
hrmy-20230630x10q.htm Edgar Link pending
hrmy-20230630xex31d1.htm Edgar Link pending
hrmy-20230630xex31d2.htm Edgar Link pending
hrmy-20230630xex32d1.htm Edgar Link pending
hrmy-20230630xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
hrmy-20230630_cal.xml Edgar Link unprocessable
hrmy-20230630_def.xml Edgar Link unprocessable
hrmy-20230630_lab.xml Edgar Link unprocessable
hrmy-20230630_pre.xml Edgar Link unprocessable
hrmy-20230630x10q_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable